Navigation Links
UC Davis bench-to-bedside research: Promising treatment in clinical trials
Date:3/26/2009

occur together and a new class of drugs that addresses both is very attractive."

Cardiologist and cell biologist Nipavan Chiamvimonvat of the UC Davis Health System and a longtime collaborator with Hammock, said many diseases tend to occur together in vascular biology. "So, a compound that addresses heart failure, as we have shown, combined with the reduction of blood pressure, inflammation and diabetes is very attractive."

The Phase IIa clinical trial is a double-blind, placebo-controlled study. Officials will enroll a total of 150 patients with impaired glucose tolerance, mild obesity and mild to moderate hypertension.

Each patient will receive 28 days of treatment. The AR9281 enzyme inhibitor will be studied for safety, tolerability, reduction of blood pressure and various measures of glucose and lipid metabolism. Results are expected the first quarter of 2010.

The winding, twisting path that took Hammock from his lab, to collaborative research with other UC Davis scientists, to his founding of a $50 million-investment biotechnology company, to clinical trials proved as steep as the mountains he climbs.

Tracing the events that led to the discovery of the enzyme, Hammock recalled doing research at UC Berkeley four decades ago with then-colleague Sarjeet Gill. Gill discovered the enzyme in mammals. Shortly after Hammock found the novel enzyme in insects.

"Both of us have been chipping away at this problem ever since," Hammock said. "By 1975 we were convinced that this was a therapeutic target but no one else was. When we finally found potent inhibitors for the enzyme that worked in whole animals, we had a tool to demonstrate that this was a promising therapeutic target."

Hammock was initially interested in regulating the development of insect larvae. With the discovery of the enzyme inhibitor, however, he switched part of his research from "pest control to pain control."

At the onset,
'/>"/>

Contact: Kathy Keatley Garvey
kegarvey@ucdavis.edu
530-754-6894
University of California - Davis
Source:Eurekalert  

Page: 1 2 3 4 5

Related biology news :

1. UC Davis research shows that newly discovered drug reduces heart enlargement
2. UC Davis researchers find molecule that targets brain tumors
3. UC Davis discovery offers hope for treating kidney cancer
4. UC Davis team refines cancer treatments to reduce potential nerve damage
5. UC Davis researchers exploring gene therapy to fight AIDS
6. UC Davis researchers discover Achilles heel in pancreatic cancer
7. UC Davis researchers discover a key to aggressive breast cancer
8. UC Davis chemical ecologist wins major award
9. UC Davis researchers discover new drug target for inflammatory disease
10. UC Davis researchers define characteristics, treatment options for XXYY syndrome
11. UC Davis researcher leads climate-change discovery
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UC Davis bench-to-bedside research: Promising treatment in clinical trials
(Date:8/22/2014)... a leading source of information for businesses and professionals, ... Riverside in its 2014 list of "some of the ... generate the list, the company analyzed citation data over ... has had enormous impact. , The following UC Riverside ... the greatest number of highly cited papers in one ...
(Date:8/22/2014)... August 21, 2014 Diabetes affects nearly 10 ... complaints of diabetics: constant finger pricking to test ... Chemical Biology reports the development of a protein ... accurate results for diabetes patients. In the American ... Daunert, Ph.D., shows off her "designer protein" that ...
(Date:8/22/2014)... (Edmonton) Thanks to important discoveries in basic and ... cancer has mobilized into a complex offensive spanning ... of Alberta chemistry lab could help find new ... developed a compound that targets a specific enzyme ... activity in cells from brain tumours. , Chemistry ...
Breaking Biology News(10 mins):5 UC Riverside scientists among world's most influential scientific minds 2New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3
... Results from two French studies presented today at the ... clinical practice in the treatment of patients with severe ... demonstrated the positive potential of performing liver transplantation for ... the recommended 6-months rule (required minimum of recorded abstinence ...
... Results from two studies presented today at the International ... devices may not confer a survival advantage for severe ... among a small sub-group of patients show promise. ... is valued as a detoxification treatment option for patients ...
... for Chemoreception Sciences (AChemS), a US-based scientific organization, is ... gathering to present new information on the role of ... in humans as well as animals. Smell and taste ... senses serve as important warning systems, alerting us to ...
Cached Biology News:New insights into treatment options for patients suffering from severe alcoholic hepatitis 2New findings on taste and smell 2New findings on taste and smell 3
(Date:8/21/2014)... 2014  Decision Resources Group finds that the ... and Mexico currently faces ... approved agents, the anticipated label extension of Boehringer ... of emerging biologics will substantially increase the competitiveness ... IL-5 inhibitors will introduce a new dynamic to the ...
(Date:8/21/2014)... HONG KONG , Aug. 21, 2014  China Cord ... today announced its plan to release financial results for ... August 28, 2014, after market close in the US.  ... call at 8:00 a.m. ET on Friday, August 29, ... brief overview of the Company,s recent developments, followed by ...
(Date:8/21/2014)... 21, 2014 Ontotext S4 , ... Ontotext . Now the same enterprise hardened ... structured and unstructured data is available to start-ups and ... enterprise technology. Organizations that do not have resources to ... can use S4 since there is no need for ...
(Date:8/21/2014)... of last week RENU 28, the world's first and only ... purchase in Australia and New Zealand, and the response has ... if you think about the definition of aging, it's really ... your body. If you think about the definition of anti-aging, ... RENU 28 does is it works with these tiny little ...
Breaking Biology Technology:Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4RENU 28 Skin Care Now Available in Australia and New Zealand 2
... a pair of information-carrying molecules: DNA and RNA. These ... they display hereditymeaning they can encode and pass on ... processes of Darwinian evolution. A long-debated question ... molecules other than DNA and RNA. John ...
... new applications based on nanoimprinting techniques (NIL) is evolving at ... be overcome in order to reach the market? How do ... from the industry? What are the tools needed for each ... this topic, i.e. Nanopatterning, Production and Applications based on Nanoimprinting ...
... April 19, 2012 RayBiotech, Inc. today announced that ... diagnostic core facilities at academic and government research institutes ... of the partnership program, core diagnostics facilities will be ... a component of their current services offerings at no ...
Cached Biology Technology:Strange cousins: Molecular alternatives to DNA, RNA offer new insight into life's origins 2Strange cousins: Molecular alternatives to DNA, RNA offer new insight into life's origins 3Strange cousins: Molecular alternatives to DNA, RNA offer new insight into life's origins 4Low-cost optical components through nanoimprinting lithography 2Low-cost optical components through nanoimprinting lithography 3RayBiotech, Inc. Announces New Diagnostic Core Facility Partnering Program 2
alpha/beta-Tubulin Antibody Ship: Hot Store: -20 C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
TXNL2 Antibody...
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Biology Products: